Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 24, 2024; 15(8): 1033-1047
Published online Aug 24, 2024. doi: 10.5306/wjco.v15.i8.1033
Prognostic value and predictive model of tumor markers in stage I to III gastric cancer patients
Ai-Hua Sun, Xin-Yu Zhang, Yang-Yang Huang, Lei Chen, Qing Wang, Xiao-Cong Jiang
Ai-Hua Sun, Xin-Yu Zhang, Xiao-Cong Jiang, Department of Radiotherapy Oncology, Huizhou Municipal Central Hospital, Huizhou 516001, Guangdong Province, China
Yang-Yang Huang, Department of Hepatobiliary Surgery, Fujian Provincial Hospital, Fuzhou 350001, China
Lei Chen, Qing Wang, Department of General Surgery, Xiang'an Hospital of Xiamen University, Xiamen 361102, Fujian Province, China
Co-corresponding authors: Qing Wang and Xiao-Cong Jiang.
Author contributions: Sun AH write the main work; Zhang XY, Huang YY, Chen L helped write the manuscript; Wang Q and Jiang XC designed this study. All authors read and approved the final manuscript.
Institutional review board statement: This study was approved by Institutional Review Board of the Huizhou Municipal Central Hospital.
Informed consent statement: This study was approved by Institutional Review Board of the Huizhou Municipal Central Hospital.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data used to support the findings of this study are available from the corresponding author upon request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Cong Jiang, Chief Doctor, Department of Radiotherapy Oncology, Huizhou Municipal Central Hospital, No. 41 Eling North Road, Huizhou 516001, Guangdong Province, China. onion1021@163.com
Received: March 20, 2024
Revised: July 3, 2024
Accepted: July 24, 2024
Published online: August 24, 2024
Processing time: 149 Days and 5.1 Hours
Abstract
BACKGROUND

Preoperative serum tumor markers have been widely used in the diagnosis and treatment of gastric cancer patients. However, few studies have evaluated the prognosis of gastric cancer patients by establishing statistical models with multiple serum tumor indicators.

AIM

To explore the prognostic value and predictive model of tumor markers in stage I and III gastric cancer patients.

METHODS

From October 2018 to April 2020, a total of 1236 patients with stage I to III gastric cancer after surgery were included in our study. The relationship between serum tumor markers and clinical and pathological data were analyzed. We established a statistical model to predict the prognosis of gastric cancer based on the results of COX regression analysis. Overall survival (OS) was also compared across different stages of gastric cancer.

RESULTS

The deadline for follow-up was May 31, 2023. A total of 1236 patients were included in our study. Univariate analysis found that age, clinical stage, T and N stage, tumor location, differentiation, Borrmann type, size, and four serum tumor markers were prognostic factors of OS (P < 0.05). It was shown that clinical stage, tumor size, alpha foetoprotein, carcinoembryonic antigen, CA125 and CA19-9 (P < 0.05) were independent prognostic factors for OS. According to the scoring results obtained from the statistical model, we found that patients with high scores had poorer survival time (P < 0.05). Furthermore, in stage I patients, the 3-year OS for scores 0-3 ranged from 96.85%, 95%, 85%, and 80%. In stage II patients, the 3-year OS for scores 0-4 were 88.6%, 76.5%, 90.5%, 65.5% and 60%. For stage III patients, 3-year OS for scores 0-6 were 70.9%, 68.3%, 64.1%, 50.9%, 38.4%, 18.5% and 5.2%. We also analyzed the mean survival of patients with different scores. For stage I patients, the mean OS was 55.980 months. In stage II, the mean OS was 51.550 months. The mean OS for stage III was 39.422 months.

CONCLUSION

Our statistical model can effectively predict the prognosis of gastric cancer patients.

Keywords: Gastric cancer; Tumor marker; Prognosis; Overall survival; Model

Core Tip: Gastric cancer is one of the most common malignant tumors in the world, few studies have established models to evaluate the prognosis of gastric cancer patients by preoperative serum tumor markers. The relevance between serum tumor markers and clinical and pathological data was analyzed in this study. We established a statistical model to predict the prognosis of gastric cancer, The perspective model can be helpful for the diagnosis and treatment of gastric cancer.